4.7 Article

Characteristics and Effect of Anxiety and Depression Trajectories in Inflammatory Bowel Disease

Journal

AMERICAN JOURNAL OF GASTROENTEROLOGY
Volume 118, Issue 2, Pages 304-316

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.14309/ajg.0000000000002063

Keywords

-

Ask authors/readers for more resources

This study observed that symptoms of anxiety or depression in patients with inflammatory bowel disease (IBD) are associated with adverse clinical outcomes. The study reported on the trajectories of these symptoms, patient characteristics associated with different trajectories, and their effects on healthcare utilization and prognosis.
INTRODUCTION: Symptoms of common mental disorders, such as anxiety or depression, are associated with adverse clinical outcomes in inflammatory bowel disease (IBD). We report trajectories of these symptoms in IBD, patient characteristics associated with different trajectories, and effects on healthcare utilization and prognosis.METHODS: We collected demographic, symptom, psychological, and quality-of-life data, with questionnaires at 3-month intervals, over 12 months of follow-up. We collected healthcare utilization and IBD outcomes through notes review. We compared characteristics of those with persistently normal or improving anxiety or depression scores with those with persistently abnormal or worsening scores and the number of flares, glucocorticosteroid prescriptions, escalations of therapy, hospitalizations, or intestinal resections due to IBD activity.RESULTS: Among 771 and 777 patients, respectively, worsening or persistently abnormal anxiety or depression scores were associated with increased antidepressant (28.6% vs 12.3% anxiety, 35.8% vs 10.1% depression, P < 0.001) and opiate use (19.0% vs 7.8% anxiety, P = 0.001 and 34.0% vs 7.4% depression, P < 0.001), compared with those with persistently normal or improving scores. These individuals were also more likely to have been diagnosed with IBD in the last 12 months (16.3% vs 5.0% anxiety, P = 0.001, and 15.1% vs 5.5% depression, P = 0.006), to have clinically active disease at baseline (57.1% vs 26.6% anxiety and 71.7% vs 29.1% depression, P < 0.001) and lower quality-of-life scores (P < 0.001). Individuals with worsening or persistently abnormal trajectories of anxiety or depression required significantly more outpatient appointments, radiological investigations, and endoscopic procedures for IBD-related symptoms.DISCUSSION: In this 12-month follow-up study, patients with IBD with worsening or persistently high anxiety or depression scores were higher utilizers of health care but were not at an increased risk of future adverse disease outcomes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Gastroenterology & Hepatology

Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis

Brigida Barberio, Pierfrancesco Visaggi, Edoardo Savarino, Nicola de Bortoli, Christopher J. Black, Alexander C. Ford

Summary: This study conducted a network meta-analysis to evaluate the efficacy and safety of different medical therapies for endoscopy-negative reflux disease. The results showed that proton pump inhibitors (PPIs) are superior to other drugs in treating this condition. Future research should focus on better patient classification and investigating the efficacy of other drugs.

NEUROGASTROENTEROLOGY AND MOTILITY (2023)

Article Gastroenterology & Hepatology

Willingness to pay for medications among patients with Rome IV irritable Bowel syndrome

Vivek C. Goodoory, Cho Ee Ng, Christopher J. Black, Alexander C. Ford

Summary: This study examined willingness to pay for medications among individuals with irritable bowel syndrome (IBS). The results showed that women and individuals with an annual income of 30,000 pounds or more were more likely to be willing to pay for medication. In addition, individuals with lower IBS-related quality of life were more willing to pay for a medication that could improve their symptoms.

NEUROGASTROENTEROLOGY AND MOTILITY (2023)

Article Gastroenterology & Hepatology

Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome

Vivek C. C. Goodoory, Elspeth A. A. Guthrie, Cho E. E. Ng, Christopher J. J. Black, Alexander C. C. Ford

Summary: Irritable bowel syndrome (IBS) has a substantial impact on the quality of life of affected individuals, and the negative impact is worse than observed in some severe chronic organic conditions.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Review Gastroenterology & Hepatology

Efficacy and Safety of Drugs for Gastroparesis: Systematic Review and Network Meta-analysis

Maria Rosa Ingrosso, Michael Camilleri, Jan Tack, Gianluca Ianiro, Christopher J. Black, Alexander C. Ford

Summary: This study evaluated the efficacy and safety of drugs for gastroparesis through a network meta-analysis. The results showed that oral dopamine antagonists and tachykinin-1 antagonists were more effective than placebo. For individual symptoms, oral metoclopramide showed good efficacy for nausea, fullness, and bloating. However, the confidence in the evidence for most comparisons was low to moderate, indicating a need for more effective therapies for gastroparesis.

GASTROENTEROLOGY (2023)

Article Gastroenterology & Hepatology

Impact of Baseline Disease Activity and Trial Duration on Efficacy of Biologics in Active Crohn's Disease: Meta-analysis

Brigida Barberio, David J. Gracie, Christopher J. Black, Alexander C. Ford

Summary: In this study, the authors conducted a systematic review and meta-analysis to evaluate the impact of criteria used to define CD activity at study entry and the time point used to confirm efficacy on the therapeutic gain of active drug over placebo. The results showed that both factors appeared to be important in maximizing the treatment effect of active drug compared to placebo.

INFLAMMATORY BOWEL DISEASES (2023)

Editorial Material Gastroenterology & Hepatology

Editorial: definition of factors associated with poor quality of life in patients with IBS-but where to from here? Authors' reply

Vivek C. Goodoory, Elspeth A. Guthrie, Cho Ee Ng, Christopher J. Black, Alexander C. Ford

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Article Gastroenterology & Hepatology

Prevalence and impact of faecal incontinence among individuals with Rome IV irritable bowel syndrome

Vivek C. Goodoory, Cho E. Ng, Christopher J. Black, Alexander C. Ford

Summary: This study compared the characteristics of individuals with irritable bowel syndrome (IBS) reporting faecal incontinence (FI) with those who do not report FI. The results showed that individuals with FI were older, more likely to have IBS-D, had lower education levels and incomes, reported more urgency and more severe IBS and psychological symptoms, had lower quality of life scores, and higher healthcare costs.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Article Gastroenterology & Hepatology

A prospective comparison of UK and Malaysian patients with irritable bowel syndrome in secondary care

Kee-Huat Chuah, Christopher J. Black, Vincent Tee, Sze-Zee Lim, Wen-Xuan Hian, Nur-Fazimah Sahran, Yeong-Yeh Lee, Sanjiv Mahadeva, Alexander C. Ford

Summary: By comparing IBS patients from the UK and Malaysia, it was found that UK patients were more likely to consume alcohol, had more frequent symptoms such as pain, bloating, and meal-related issues, higher symptom scores, greater limitation of activities, and a higher likelihood of reporting abnormal anxiety. UK patients also had higher levels of perceived stress, gastrointestinal symptom-specific anxiety, and somatoform symptom-reporting.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Editorial Material Gastroenterology & Hepatology

Editorial: faecal incontinence is prevalent in IBS, as are effective treatment options! Authors' reply

Vivek C. Goodoory, Cho Ee Ng, Christopher J. Black, Alexander C. Ford

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Letter Gastroenterology & Hepatology

Letter: Does irritable bowel syndrome have a greater impact in Western, compared with Asian, patients? Authors' reply

Vivek C. Goodoory, Elspeth A. Guthrie, Cho Ee Ng, Christopher J. Black, Alexander C. Ford

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Letter Gastroenterology & Hepatology

Letter: determining priorities for patients with faecal incontinence and irritable bowel syndrome--authors' reply

Vivek C. Goodoory, Cho E. Ng, Christopher J. Black, Alexander C. Ford

Summary: This article is associated with Goodoory et al papers. Click the link to access these articles.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Article Gastroenterology & Hepatology

Novel symptom clusters predict disease impact and healthcare utilisation in inflammatory bowel disease: Prospective longitudinal follow-up study

Christy Riggott, Keeley M. Fairbrass, Christopher J. Black, David J. Gracie, Alexander C. Ford

Summary: Using latent class analysis, this study identified novel clusters of patients with inflammatory bowel disease (IBD) and found that patients with higher gastrointestinal and psychological symptoms were at a higher risk of adverse disease outcomes and were also high-volume users of healthcare.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Editorial Material Gastroenterology & Hepatology

Editorial: Recognising the regional variations in profile of irritable bowel syndrome-better late than never! Authors' reply

Kee-Huat Chuah, Christopher J. Black, Vincent Tee, Sze-Zee Lim, Wen-Xuan Hian, Nur-Fazimah Sahran, Yeong-Yeh Lee, Sanjiv Mahadeva, Alexander C. Ford

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Editorial Material Psychiatry

Seryan Atasoy, 2023 EAPM Elsevier Young Investigator Award recipient, on stability of somatic symptoms

Jess G. Fiedorowicz, Else Guthrie, Bernd Loewe

JOURNAL OF PSYCHOSOMATIC RESEARCH (2023)

Editorial Material Gastroenterology & Hepatology

Neurogastroenterology and Motility gets younger!

Maura Corsetti, Andrea Shin, Christopher Black, Daniel Keszthelyi, Fedias L. Christofi, Frank Zerbib, Kirsteen Browning, Michael Jones

NEUROGASTROENTEROLOGY AND MOTILITY (2023)

No Data Available